CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
Site Search
Showing 1 - 3 of 3 results
News
|
Sept. 1, 2022
|
3 min read
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
News
|
Sept. 2, 2022
|
3 min read
Revised approach to lung function reporting is shown to be more scientifically accurate and may reduce health disparities.
News
|
April 2, 2024
|
5 min read